1. Home
  2. STTK vs MOBI Comparison

STTK vs MOBI Comparison

Compare STTK & MOBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$4.55

Market Cap

474.6M

Sector

Health Care

ML Signal

N/A

Logo Mobia Medical Inc. Common Stock

MOBI

Mobia Medical Inc. Common Stock

N/A

Current Price

$11.85

Market Cap

383.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
MOBI
Founded
2016
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
474.6M
383.0M
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
STTK
MOBI
Price
$4.55
$11.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
4
Target Price
$15.40
★ $18.00
AVG Volume (30 Days)
★ 841.6K
178.6K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 53.02
N/A
EPS
★ N/A
N/A
Revenue
★ $1,000,000.00
N/A
Revenue This Year
N/A
$71.88
Revenue Next Year
$14.28
$43.02
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.89
$8.03
52 Week High
$8.33
$15.19

Technical Indicators

Market Signals
Indicator
STTK
MOBI
Relative Strength Index (RSI) 36.78 51.80
Support Level $4.38 $10.55
Resistance Level $7.66 $11.98
Average True Range (ATR) 0.39 1.18
MACD -0.02 0.02
Stochastic Oscillator 14.29 47.40

Price Performance

Historical Comparison
STTK
MOBI

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About MOBI Mobia Medical Inc. Common Stock

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.

Share on Social Networks: